● LIVE
NIFTY 5023,115.200.43%BANK NIFTY55,078.900.04%FINNIFTYINDIA VIX15.620.06%NIFTY IT27,588.202.45%NIFTY AUTO25,633.000.78%NIFTY MID13,920.500.51%USD/INR95.40NIFTY 5023,115.200.43%BANK NIFTY55,078.900.04%FINNIFTYINDIA VIX15.620.06%NIFTY IT27,588.202.45%NIFTY AUTO25,633.000.78%NIFTY MID13,920.500.51%USD/INR95.40NIFTY 5023,115.200.43%BANK NIFTY55,078.900.04%FINNIFTYINDIA VIX15.620.06%NIFTY IT27,588.202.45%NIFTY AUTO25,633.000.78%NIFTY MID13,920.500.51%USD/INR95.40
Login☆ Watchlist
Markets
NSE StocksBSE StocksF&ORates & G-SecsCurrenciesSectorsCommoditiesIPOs
News
Corporate AnnouncementsGovernment & PolicyFixed IncomeETFsFXAlt. InvestingStartupsEconomic Calendar
Sections
EconomicsTechFinancePoliticsWealth

CONCORDBIO

BSE
Concord Biotech Limited
Healthcare· Pharmaceuticals & Biotechnology· INE338H01029· Scrip: 543960
ENहिन्दीગુજરાતીमराठी
1,326.85
55.30 (+0.00%)
2026-06-10
BSE
1,326.85
55.30
+0.00%
1,0101,2461,4821,7181,95406-2308-1410-1012-0502-0204-0206-10
228 trading days · 1Y period
TODAY (BSE)
Open1,288.90
High1,349.70
Low1,285.05
Prev Close1,271.55
Volume81,640
Value₹10.9Cr
L: 1,285.05H: 1,349.70
Info
Face Value₹1
Listed2023-08-18
ISININE338H01029
SeriesA
BSE Scrip543960

Key Metrics

1D
1W
1M
3M
6M
Growth (QoQ)
Revenue-21.27%
PAT-20.70%
EPS-20.66%
Profitability
Dividend
Latest DPS₹10.7
Growth+22.29%
TTM Revenue
₹1089 Cr
TTM EBITDA
₹610 Cr
TTM PAT
₹326 Cr
TTM EPS
₹31.19
Rev/Share
₹104.1

Quarterly Financials

Revenue
EBITDA
PAT
EPS
0 Cr80 Cr159 Cr239 Cr319 Cr23-0623-0923-1224-0324-0624-0924-125.27.77.49.15.79.27.3
QuarterRevenueExpensesEBITDAPBTPATEPS
2024-12-31244 Cr160 Cr138 Cr99 Cr76 Cr7.26
2024-09-30310 Cr187 Cr181 Cr133 Cr96 Cr9.15
2024-06-30216 Cr148 Cr112 Cr78 Cr60 Cr5.70
2024-03-31319 Cr199 Cr179 Cr131 Cr95 Cr9.08
2023-12-31241 Cr149 Cr140 Cr100 Cr78 Cr7.41
2023-09-30262 Cr157 Cr156 Cr113 Cr81 Cr7.74
2023-06-30195 Cr136 Cr95 Cr65 Cr54 Cr5.21

Shareholding Pattern

CURRENT2026-03-31
44.1%PROMOTER
Promoter44.1%
FII7.8%
DII9.2%
Public55.9%
PROMOTER HOLDING TREND
44.1%24-0644.1%24-0944.1%24-1244.1%25-0344.1%25-0944.1%25-1244.1%26-03

Corporate Actions

Ex-DateTypePurpose
2025-09-03DividendDividend - Rs 10.70 Per Share
2024-06-21OtherAnnual General Meeting
2024-06-21DividendDividend - Rs 8.75 Per Share

Earnings Transcripts

Price History

DateOpenHighLowCloseVolume
2026-06-101,284.001,349.901,282.601,330.7012.15L
2026-06-031,230.001,273.001,189.001,201.5060.55L
2026-05-271,135.101,145.501,096.201,099.601.38L
2026-05-261,131.001,144.001,131.001,138.8058,229
2026-05-251,176.401,180.001,130.001,131.901.05L
2026-05-221,129.001,176.901,116.101,153.302.00L
2026-05-211,116.501,137.901,110.101,123.3043,441
2026-05-201,141.001,165.501,106.701,116.001.12L
2026-05-191,127.001,150.001,127.001,143.5083,722
2026-05-181,127.101,130.001,099.401,125.201.16L
2026-05-151,140.001,149.401,112.701,135.3067,969
2026-05-141,140.001,157.801,122.601,140.001.05L
2026-05-131,130.001,167.901,124.801,131.001.05L
2026-05-121,200.601,203.901,115.901,127.202.00L
2026-05-111,177.001,214.601,150.401,198.802.07L
2026-05-081,198.101,202.401,168.001,173.901.56L
2026-05-071,224.001,234.201,190.001,198.701.84L
2026-05-061,185.001,233.901,185.001,222.002.22L
2026-05-051,201.201,208.201,150.101,184.802.23L
2026-05-041,158.901,216.401,143.501,195.204.46L
2026-04-301,140.001,154.201,119.501,142.002.99L
2026-04-291,074.301,164.101,073.001,134.509.51L
2026-04-281,062.001,122.001,060.501,072.005.24L
2026-04-271,027.201,075.601,022.801,057.903.06L
2026-04-241,059.301,068.901,010.201,016.201.86L
2026-04-231,052.401,069.101,044.901,050.202.21L
2026-04-221,046.001,058.001,033.301,052.201.17L
2026-04-211,066.401,073.701,037.501,043.701.80L
2026-04-201,080.501,088.001,055.101,066.403.37L
2026-04-171,048.001,113.601,041.301,081.707.77L

Frequently Asked Questions

About

Concord Biotech Limited, incorporated in 1984, is an Indian biotechnology company headquartered in Ahmedabad specializing in the manufacturing of fermentation-based active pharmaceutical ingredients (APIs) and high-quality formulations. With over two and a half decades of expertise, they serve the global pharmaceutical market, focusing on immunosuppressants and oncology, and are recognized as a leading biopharmaceutical manufacturer in India.

BOARD OF DIRECTORS
Anil Katyal
Independent Director
DEPARTED
Utpal Hemendra Sheth
Independent Director
DEPARTED
Amit Varma
Director
DEPARTED

Mutual Fund Holdings

1 funds · bar length = % to NAVBrowse all funds →
hdfc1 scheme
HDFC NIFTY SMALLCAP 250 INDEX FUND
0.20%
₹1 Cr